Skip to main content
. 2011 Oct 17;40(3):1174–1190. doi: 10.1093/nar/gkr821

Figure 5.

Figure 5.

In vitro deacetylation of the N-terminal peptide (specific to PfAlba3) by recombinant PfSir2A. HPLC chromatograms showing absorbance at 210 nm using (A) non-acetylated and K22Ac peptide only, (B) K22Ac peptide incubated with PfSir2A, without NAD+, (C) K22Ac peptide with PfSir2A, NAD+ (20 µM), (D) K22Ac peptide with PfSir2A, NAD+ (100 µM), (E) K22Ac peptide with PfSir2A, NAD+ (500 µM), (F) non-acetylated and K23Ac peptide only, (G) K23Ac peptide incubated with PfSir2A, without NAD+, (H) K23Ac peptide with PfSir2A, NAD+ (20 µM), (I) K23Ac peptide with PfSir2A, NAD+ (100 µM), (J) K23Ac peptide with PfSir2A, NAD+ (500 µM), respectively. Box representing the peptide sequence used in deacetylation reaction.